VEGFA and age-related macular degeneration: The higher prevalence of thisage group is justified by the finding that the main pathologies indicative oftreatment with anti-VEGF injection in this study were DME (48.25%) followed byexudative AMD (12.25%), which are common in older groups (Table 2) .